Endocrine Abstracts

Introduction: Achieving glycemic goals remains a challenge for many people with T1D despite recent technological advances. Integrated systems and closed loops pumps have shown significant improvements in glycemic control in clinical studies as well as in real life conditions.Objective: Assess the performance of the systems Tandem Control-IQ and DIABELOOP in people with T1D comparing the glucosa readings before and after having the device for 14 days....

Adrenocortical cancer (ACC) is a rare cancer with poor prognosis and scant treatment options.Purpose: To look for new therapeutic approaches issued from the screening for common genetic variants in a large series of advanced ACC.Experimental design: Whole exome sequencing have been performed in 10 advanced (stage III and IV) ACC samples to identify the recurrent variants. The presence and the frequency of most interesting variants ...

Introduction: Primary hypothyroidism, as a clinical syndrome caused by insufficiency or inefficacy of thyroid hormones, significantly influences on patients’ quality of life (QoL). Accelerated atherosclerosis induces increased cardiovascular morbidity and mortality rates in hypothyroid patients. Serum NO2 levels, the stable NO metabolites, are among well-known markers for endothelial dysfunction and atherosclerosis in hypothyroidism. We examined the correlation between se...

Introduction: The Disorders of Sex Development (DSDs) may arise from various genetic disorders therefore cytogenetic studies are necessary to determine the chromosomal sex. The 45,X/46,XY karyotype is considered a mixed gonadal dysgenesis (MGD) and the mosaicism in this condition has a low incidence: 1.5 per 10 000 newborns, characterized by a broad phenotypic spectrum.Objective: The aim of this report is to present a mexican newborn female patient with ...

Chimeric somatostatin (SST)/dopamine (DA) compounds, termed dopastatins, such as BIM-23A760, an agonist for SST (sst2 and ss5) and DA (D2) receptors, are emerging as promising new approaches to treat pituitary adenomas. However, their actions and mechanisms on the different types of pituitary tumours are still incompletely understood. Thus, the aim of this study was to analyse a set of key functional parameters (signaling pathways, hormonal expression and secretion, cell viabi...

Pituitary adenomas comprise a heterogeneous group of tumours causing serious comorbidities, which would benefit from identification of novel, common molecular/cellular biomarkers and therapeutic targets. The ghrelin system comprises a complex molecular family with multiple functions, and some of its components have been linked to development of various endocrine-related cancers. In this work we aim at better delineating the patho-physiological significance of the ghrelin regul...

Somatostatin analogs (SSA) are a first-line treatment for pituitary adenomas (PA). Indeed, multi-receptor targeting SSA such as octreotide and pasireotide are being successfully used to control hormone secretion and/or tumor growth. Unfortunately, many PA escape from SSA-therapy, which could be related to somatostatin receptor (sst) presence, abundance, availability and/or signaling. In order to better define the molecular/cellular features associated to octreotide and pasireo...

Introduction: Semaglutide is a GLP1 receptor agonist (GLP1RA) recently approved in Spain for the treatment of Type 2 Diabetes (T2D) and the National Health Service finances it for patients with T2D and body mass index (BMI) > 30 with a poor metabolic control with metformin.Objectives: Evaluate the effects of Semaglutide on glycemic control and body composition in patients with T2D (PwT2D) and obesity after 6 months of use in a real life setting.<...

Background: NAFLD(non–alcoholic fatty liver disease) includes; non–alcoholic fatty liver(NAFL), non–alcoholic steatohepatitis (NASH) and its complications (fibrosis, cirrhosis and hepatocellular carcinoma). These diseases are currently the most common cause of liver disease in western countries, due to the obesity and DM2 epidemic. There are scores that determine the risk of liver fibrosis in a non–invasive way.Aims: To determine ...

Objectives: Semaglutide was approved for the treatment of T2DM patients with a body mass index (BMI) > 30kg/m2 by the Spanish National Health Service in May 2019. We evaluate clinical outcomes of patients on previous treatment with any another GLP1–RA that switch to Semaglutide.Material and Methods: Retrospective analysis. Sixty–five T2DM patients were included. Demographic data, anthropometric, systolic blood pressure (SBP), d...